Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/18180

Title: Implementation of transmural disease management in patients admitted with advanced heart failure
Authors: Duchenne, Jurgen
DUPONT, Matthias
Vercammen, Jan
Jacobs, Linda
MULLENS, Wilfried
Issue Date: 2014
Citation: ACTA CARDIOLOGICA, 69 (2), p. 145-154
Abstract: Objective The objective of this study was to assess the feasibility and impact on readmissions of transmural disease management across the borders of the cardiology department in patients with advanced heart failure (HF). Methods and results Consecutive patients, readmitted within one year for advanced HF by a dedicated specialist (n = 55), were followed for 22 10 months after implementation of a hospitalwide transmural disease management strategy. Participants received a tag in their electronic medical record, triggering a HF caregiver contact, with subsequent guideline-recommended, protocol-driven care on each cardiac or non-cardiac hospitalization as well as outpatient evaluation. Upon transition to outpatient follow-up, patients were instructed to call the HF caregiver with any question at low threshold. Readmission rates were prospectively collected. Despite receiving adequate treatment with neurohumoral blockers, patients (71 +/- 11 years; ejection fraction 35 +/- 13%) had spent 4% (27%) of the year preceding study inclusion in hospital, with 73% admitted once, 20% twice, and 7% more than twice for acute decompensated HF (ADHF). During the study, patients were exposed to 6 4 dedicated HF caregiver contacts. Participation in remote device monitoring increased from 31% to 92%, with 1(0-3) additional phone contacts per patient-year of follow-up in this subgroup (n = 24). All-cause mortality and readmission rates for ADHF were 10% and 25% after one year, and 19% and 39% after 2 years, respectively. Follow-up time spent in hospital decreased significantly to 2% (16%) (P value = 0.047). Conclusions Follow-up of advanced HF patients through transmural disease management is feasible and associated with favourable clinical outcome.
Notes: [Duchenne, Jurgen; Verbrugge, Frederik H.; Dupont, Matthias; Vercammen, Jan; Jacobs, Linda; Grieten, Lars; Vandervoort, Pieter; Mullens, Wilfried] Ziekenhuis Oost Limburg, Dept Cardiol, B-3600 Genk, Belgium. [Duchenne, Jurgen] Transnat Univ Limburg, Fac Med & Life Sci, Dept Life Sci, Hasselt, Belgium. [Verbrugge, Frederik H.] Hasselt Univ, Doctoral Sch Med & Life Sci, Diepenbeek, Belgium. [Grieten, Lars; Vandervoort, Pieter; Mullens, Wilfried] Hasselt Univ, Fac Med & Life Sci, Biomed Res Inst, Diepenbeek, Belgium.
URI: http://hdl.handle.net/1942/18180
DOI: 10.2143/AC.69.2.3017295
ISI #: 000346681200005
ISSN: 0001-5385
Category: A1
Type: Journal Contribution
Validation: ecoom, 2016
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
N/A1.2 MBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.